![]() Key elements driving this expected growth are improved technologies and new drug approvals in western countries. This represents a forecast CAGR (Compound Annual Growth Rate) of 4.4% from 2015 to 2025. Market & CompetitionĪccording to a 2017 market research report by GlobalData, the global market for Her2+ breast cancer treatments in the eight major markets (7MM plus urban China) was an estimated $6.4 billion in 2015 and was expected to reach $9.9 billion in 2025. Venture Partners, Hunt Pacific, Nextech, Pontifax and EcoR1. Investors in the firm have invested at least $216 million and include OrbiMed, U.S. Other programs are in preclinical studies for treating bladder cancer, triple negative breast cancer, and head & neck cancer as well as chronic Hepatitis B.īelow is the current status of the company’s drug development pipeline: The firm's lead candidate, SBT6050, is in Phase 1/1b trials and is being developed to treat solid tumor cancers such as HER2 breast cancer, gastric cancer and non-small cell lung cancer (NSCLC). Laura Shawver, Ph.D., who has been with the firm since April 2020 and was previously president and CEO of Synthorx until its acquisition by Sanofi in January 2020.īelow is a brief overview video of HER2 Positive breast cancer treatment and research: Management is headed by Chief Executive Officer Ms. ![]() Seattle, Washington-based Silverback was founded to create what it calls its ImmunoTAC platform to develop 'systematically delivered, tissue targeted therapeutics' by pairing 'proprietary linker-payloads that modulate key disease-modifying pathways with monoclonal antibodies directed to specific disease sites.' SBTX has seen encouraging early stage trial activity for its lead program, but the very is still very early stage and interested investors would need to likely wait until 2022 for a meaningful catalyst to the stock, so I'll watch the IPO from the sidelines. The company is developing treatment candidates for various highly prevalent forms of cancer. Silverback Therapeutics ( SBTX) intends to raise $125 million from the sale of its common stock in an IPO, according to an amended registration statement. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |